Use of a broad-host-range gyrA plasmid for genetic characterization of fluoroquinolone-resistant gram-negative bacteria
Open Access
- 1 October 1991
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 35 (10) , 2031-2036
- https://doi.org/10.1128/aac.35.10.2031
Abstract
The gyrA genotypes of ciprofloxacin-resistant clinical isolates of Escherichia coli (n = 3), Klebsiella pneumoniae (n = 4), Providencia stuartii (n = 2), Pseudomonas aeruginosa (n = 1), and Acinetobacter calcoaceticus (n = 1) were analyzed in a dominance test. This test is based on the dominance of a wild-type gyrA gene (gyrA+) over the quinolone resistance allele (gyrA) in a heterodiploid strain. Plasmid pBP515, developed to carry the gyrA+ gene of E. coli K-12 on a broad-host-range vector derived from pRSF1010, was used to obtain heterodiploid strains. Plasmid pBP515 encodes kanamycin and gentamicin resistance and is transferable via mobilization by a pRP1-derived helper plasmid (pRP1H) to strains of several gram-negative species. After the introduction of pBP515, single-cell MICs (as measured by reduction of the viable cell count) of ciprofloxacin and nalidixic acid decreased by 4- to greater than 8,000-fold for all strains tested, and 8 of the 11 strains regained ciprofloxacin susceptibilities similar to those of the respective wild types. The results indicate that (i) high-level fluoroquinolone resistance in clinical isolates of E. coli, K. pneumoniae, P. aeruginosa, and A. calcoaceticus can result from mutational alteration of the gyrA gene, and (ii) gyrA mutations are involved in high levels of fluoroquinolone resistance in P. stuartii. Additional mutations outside the gyrA locus may contribute to resistance in K. pneumoniae and P. stuartii.Keywords
This publication has 40 references indexed in Scilit:
- Persistence of Pseudomonas aeruginosa during ciprofloxacin therapy of a cystic fibrosis patient: transient resistance to quinolones and protein F-deficiencyJournal of Antimicrobial Chemotherapy, 1990
- Isolation of fluoroquinolone-resistantEscherichia coli andKlebsiella pneumoniae from an infected hickman catheterEuropean Journal of Clinical Microbiology & Infectious Diseases, 1990
- Mechanisms of resistance to quinolones and clinical perspectivesJournal of Antimicrobial Chemotherapy, 1989
- In vitro activity of temafloxacin, a new difluoro quinolone antimicrobial agentEuropean Journal of Clinical Microbiology & Infectious Diseases, 1988
- Cloning and sequencing of the Escherichia coli gyrA gene coding for the a subunit of DNA gyraseJournal of Molecular Biology, 1987
- Emergence of ofloxacin-resistant Citrobacter freundii and Pseudomonas maltophiliaafter ofloxacin therapyJournal of Antimicrobial Chemotherapy, 1987
- Ciprofloxacin in the treatment of infections caused by gentamicin-resistant gram-negative bacteriaEuropean Journal of Clinical Microbiology & Infectious Diseases, 1986
- Evaluation of ciprofloxacin in the treatment ofPseudomonas aeruginosa infectionsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1986
- Specific-purpose plasmid cloning vectors II. Broad host range, high copy number, RSF 1010-derived vectors, and a host-vector system for gene cloning in PseudomonasGene, 1981
- Host Ranges of R FactorsJournal of General Microbiology, 1972